E2 ModeratePreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta.
Maes, Michael, Mihaylova, Ivana, Bosmans, Eugene · Neuro endocrinology letters · 2007
Quick Summary
This study found that people with ME/CFS have higher levels of a molecule called NF-kappa-beta in their white blood cells, both at rest and when stimulated by immune signals. This molecule controls inflammation and stress responses in cells. The higher the NF-kappa-beta levels, the more severe patients' symptoms—including fatigue, muscle pain, and feeling sick—were reported to be.
Why It Matters
This study provides biological evidence that ME/CFS involves real cellular inflammation rather than psychological causes, addressing long-standing stigma. By identifying NF-kappa-beta as a central regulatory mechanism, it offers a potential biological marker for disease severity and suggests testable therapeutic targets through antioxidant interventions.
Observed Findings
- CFS patients had significantly higher unstimulated NF-kappa-beta p50 production compared to controls (F=19.4, p=0.0002)
- TNF-alpha-stimulated NF-kappa-beta production was significantly elevated in CFS patients (F=14.0, p=0.0009)
- PMA-stimulated NF-kappa-beta production was significantly elevated in CFS patients (F=7.9, p=0.008)
- Positive correlations existed between NF-kappa-beta production levels and symptom severity measured by the FibroFatigue scale
- NF-kappa-beta levels correlated positively with specific symptoms including fatigue, muscular tension, aches, pain, irritability, sadness, and subjective infection feeling
Inferred Conclusions
- Intracellular inflammatory responses in white blood cells play an important role in ME/CFS pathophysiology
- Previously observed increases in oxidative stress and inflammation in ME/CFS may be mediated by elevated NF-kappa-beta production
- ME/CFS symptoms reflect a genuine biological inflammatory response rather than psychological or psychiatric etiology
- Antioxidants that inhibit NF-kappa-beta production warrant investigation as potential treatments for ME/CFS
Remaining Questions
- Does NF-kappa-beta elevation precede symptom onset, occur as a result of disease processes, or both?
What This Study Does Not Prove
This study does not establish that NF-kappa-beta elevation causes ME/CFS symptoms or that treating it will improve outcomes; it only shows correlation. The small sample size (n=18 per group) and cross-sectional design limit generalizability, and the study does not demonstrate whether NF-kappa-beta changes are primary drivers of pathology or secondary consequences of the disease.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
Metadata
- PMID
- 17693979
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →